Dapagliflozin FDA Approval for Type 2 Diabetes

Dapagliflozin FDA Approval for Type 2 Diabetes

Dapagliflozin CAS# 461432-26-8 FDA ApprovalAs an anti-diabetic medication and selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2), Dapagliflozin is now approved by the FDA for the treatment of type 2 diabetes mellitus. The Dapagliflozin FDA approval was announced January 13, 2014, as the brand name Farxiga, which is marketed by Bristol-Myers Squibb. The unique ability of Dapagliflozin as an inhibitor of the SGLT2 is essential for treating patients with type 2 diabetes, as this transporter is responsible for roughly 90 percent of the glucose which is reabsorbed in the kidneys. By helping patients regulate their re-absorption of filtered glucose Dapagliflozin is ideal for aiding the maintenance of glucose levels in patients overall. The newly approved form of Dapagliflozin, Farxiga, is an easy to administer once daily oral medication. The starting dose for the majority of patients is 5 milligrams of Dapagliflozin, taken once a day, but there is a 10 milligram dose to be taken once daily for those patients who need additional glucose control.

Studies of Dapagliflozin (Farxiga) have been comprehensive, with 24 individual clinical studies taking place, and over 11,000 patients with type 2 diabetes participating. The total number of patients who received Farxiga in clinical trials exceeds 6,000  people. One of the comprehensive and successful trials included a 24 week add-on study of Dapagliflozin to Metformin. The adult type 2 patients who received either 5 milligrams or 10 milligrams of Dapagliflozin, in addition to treatment with Metformin, displayed sizable reductions in their baseline HbA1c levels. Additionally, there were no major issues involving hypoglycemia among any of the patients who were administered both Metformin and the Dapagliflozin add on of either 5 or 10 milligrams.

Statistics regarding cases of type 2 diabetes are continually revised, and unfortunately always growing in estimates. Type 2 diabetes is now predicted to affect 550 million people worldwide by the year 2030, making this disease an epidemic of great proportion.

LGM Pharma provides Dapagliflozin CAS# 461432-26-8 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service